IS5140A - Atrópísómerur af 3-arýl-4(3H)-kínasólínónum og notkun þeirra ásamt lyfjablöndum - Google Patents

Atrópísómerur af 3-arýl-4(3H)-kínasólínónum og notkun þeirra ásamt lyfjablöndum

Info

Publication number
IS5140A
IS5140A IS5140A IS5140A IS5140A IS 5140 A IS5140 A IS 5140A IS 5140 A IS5140 A IS 5140A IS 5140 A IS5140 A IS 5140A IS 5140 A IS5140 A IS 5140A
Authority
IS
Iceland
Prior art keywords
quinazolinones
atropisomers
aryl
combination
pharmaceutical preparations
Prior art date
Application number
IS5140A
Other languages
English (en)
Other versions
IS1952B (is
Inventor
Willard Mckowan Welch, Jr.
Michael Devries Keith
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5140A publication Critical patent/IS5140A/is
Publication of IS1952B publication Critical patent/IS1952B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IS5140A 1997-02-28 1999-07-30 Atrópísómerur af 3-arýl-4(3H)-kínasólínónum og notkun þeirra ásamt lyfjablöndum IS1952B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3890597P 1997-02-28 1997-02-28
PCT/IB1998/000150 WO1998038173A1 (en) 1997-02-28 1998-02-06 Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists

Publications (2)

Publication Number Publication Date
IS5140A true IS5140A (is) 1999-07-30
IS1952B IS1952B (is) 2004-10-13

Family

ID=21902563

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5140A IS1952B (is) 1997-02-28 1999-07-30 Atrópísómerur af 3-arýl-4(3H)-kínasólínónum og notkun þeirra ásamt lyfjablöndum

Country Status (40)

Country Link
US (1) US6306864B1 (is)
EP (1) EP0968194B1 (is)
JP (1) JP2000509731A (is)
KR (1) KR100358636B1 (is)
CN (1) CN1248248A (is)
AP (1) AP859A (is)
AR (1) AR011170A1 (is)
AT (1) ATE267817T1 (is)
AU (1) AU744028B2 (is)
BG (1) BG103689A (is)
BR (1) BR9807872A (is)
CA (1) CA2282277C (is)
DE (1) DE69824157T2 (is)
DK (1) DK0968194T3 (is)
DZ (1) DZ2440A1 (is)
EA (1) EA001963B1 (is)
ES (1) ES2219866T3 (is)
GT (1) GT199800038A (is)
HR (1) HRP980106A2 (is)
HU (1) HUP0000914A3 (is)
ID (1) ID22711A (is)
IL (1) IL130900A0 (is)
IS (1) IS1952B (is)
MA (1) MA24484A1 (is)
NO (1) NO313630B1 (is)
NZ (1) NZ336628A (is)
OA (1) OA11089A (is)
PA (1) PA8447001A1 (is)
PE (1) PE58399A1 (is)
PL (1) PL335418A1 (is)
PT (1) PT968194E (is)
SK (1) SK113299A3 (is)
TN (1) TNSN98035A1 (is)
TR (1) TR199902093T2 (is)
TW (1) TW504508B (is)
UA (1) UA61097C2 (is)
UY (1) UY24897A1 (is)
WO (1) WO1998038173A1 (is)
YU (1) YU41299A (is)
ZA (1) ZA981666B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103772C (zh) 1996-05-15 2003-03-26 辉瑞大药厂 新的2,3-二取代-4(3h)-喹唑啉酮类化合物
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GEP20084317B (en) * 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
CA2420040C (en) 2000-08-18 2009-02-03 Ajinomoto Co., Inc. New phenylalanine derivatives
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
EP1660486A4 (en) * 2003-08-08 2006-12-13 Ulysses Pharmaceutical Product HALOGENATED CHINAZOLINYL NITROFURANES AS ANTIBACTERIAL AGENTS
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
US7345049B2 (en) 2003-12-22 2008-03-18 Ajinomoto Co., Inc. Phenylalanine derivatives
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
NZ629684A (en) 2012-03-05 2016-10-28 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
CN103275086B (zh) * 2013-05-30 2015-04-15 温州大学 一种6-取代喹唑啉并喹唑啉酮化合物及其合成方法和用途
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US9533909B2 (en) 2014-03-31 2017-01-03 Corning Incorporated Methods and apparatus for material processing using atmospheric thermal plasma reactor
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
DE102014217021A1 (de) * 2014-08-27 2016-03-03 Skf Lubrication Systems Germany Ag Gehäuse für eine Vorrichtung zum dosierten Verteilen eines Mediums sowie eine Dosiereinrichtung zur Verwendung in dem Gehäuse
MA54460A (fr) 2018-12-14 2021-10-20 Eisai R&D Man Co Ltd Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine
WO2021154966A1 (en) 2020-01-29 2021-08-05 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) * 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5777271A (en) * 1996-01-18 1998-07-07 Commscope, Inc. Cable having an at least partially oxidized armor layer
CN1103772C (zh) * 1996-05-15 2003-03-26 辉瑞大药厂 新的2,3-二取代-4(3h)-喹唑啉酮类化合物

Also Published As

Publication number Publication date
AU744028B2 (en) 2002-02-14
NO994177D0 (no) 1999-08-27
CN1248248A (zh) 2000-03-22
PE58399A1 (es) 1999-06-16
CA2282277C (en) 2005-10-11
DZ2440A1 (fr) 2003-01-11
HUP0000914A3 (en) 2001-09-28
HUP0000914A2 (hu) 2001-04-28
IL130900A0 (en) 2001-01-28
GT199800038A (es) 1999-08-13
NZ336628A (en) 2001-03-30
OA11089A (en) 2003-09-22
ZA981666B (en) 1999-08-27
DE69824157D1 (de) 2004-07-01
TW504508B (en) 2002-10-01
NO994177L (no) 1999-08-27
NO313630B1 (no) 2002-11-04
KR20000075814A (ko) 2000-12-26
EP0968194A1 (en) 2000-01-05
UY24897A1 (es) 2000-12-29
UA61097C2 (uk) 2003-11-17
AP859A (en) 2000-07-21
JP2000509731A (ja) 2000-08-02
TNSN98035A1 (fr) 2005-03-15
ATE267817T1 (de) 2004-06-15
PT968194E (pt) 2004-08-31
AP9801199A0 (en) 1998-03-31
US6306864B1 (en) 2001-10-23
IS1952B (is) 2004-10-13
AU5676898A (en) 1998-09-18
EA199900693A1 (ru) 2000-02-28
ES2219866T3 (es) 2004-12-01
MA24484A1 (fr) 1998-10-01
AR011170A1 (es) 2000-08-02
SK113299A3 (en) 2001-05-10
BG103689A (bg) 2000-11-30
WO1998038173A1 (en) 1998-09-03
EP0968194B1 (en) 2004-05-26
EA001963B1 (ru) 2001-10-22
BR9807872A (pt) 2000-03-21
PA8447001A1 (es) 2000-05-24
ID22711A (id) 1999-12-09
CA2282277A1 (en) 1998-09-03
PL335418A1 (en) 2000-04-25
TR199902093T2 (xx) 1999-12-21
HRP980106A2 (en) 1999-02-28
YU41299A (sh) 2002-09-19
DE69824157T2 (de) 2004-10-14
KR100358636B1 (ko) 2002-10-31
DK0968194T3 (da) 2004-08-16

Similar Documents

Publication Publication Date Title
IS1952B (is) Atrópísómerur af 3-arýl-4(3H)-kínasólínónum og notkun þeirra ásamt lyfjablöndum
DK0723774T3 (da) Anvendelse af en antagonist for CGRP i en kosmetisk, farmaceutisk eller dermatologisk sammensætning og den opnåede sammensæ
NO972236D0 (no) Dihydropyrimidiner og anvendelse derav
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO975309L (no) Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C
DE69738197D1 (de) Azolotriazine und pyrimidine
HUP0101137A3 (en) Anticoagulant amidines and their pharmaceutical use
EE04566B1 (et) Epotilooni derivaadid ja nende kasutamine meditsiinis
DE60138768D1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
DE69836424D1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
DE69824175D1 (de) Nachfüllbarer stent und verabreichungssystem
PT1270565E (pt) Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
HUP9902655A3 (en) Pharmaceutical composition of hedgehog proteins and use thereof
DK1017408T3 (da) Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK0994706T3 (da) Præparater til oral indgivelse af taxaner og anvendelse deraf
NO20001905D0 (no) Forbindelser og deres anvendelse i farmasøytiske eller kosmetiske preparater
NO20003410D0 (no) Fremstilling og anvendelse av blandede opalescerende midler basert pÕ titan- og silisiumoksyder
DK0983271T3 (da) Carbocyklisk nucleosidhemisulfat og anvendelsen deraf i behandlingen af virusinfektioner
ITMI942663A0 (it) Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le compongono
ATE281166T1 (de) Tizoxanide und/oder nitazoxanide enthaltende pharmazeutische zubereitungen
EP1161451A4 (en) HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
DK0776899T3 (da) Mellemprodukter og deres anvendelse til fremstilling af N,N'-forbundne bisindolylmaleimider